Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 13 | 2023Rybelsus Approved as First-Line Therapy for T2DM; Biocon Receives Another CRL; Tandem Initiates Control-IQ 2.0 Feasibility Study in T1DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Jan 12 | 2023JPM 2023 Day 4: TNDM, ICPT, LXRX, MNKD, and XERS; Oramed Discontinues Ph3 Development ORMD-0801 in T2DM; Versanis Initiates Ph2b Obesity Trial EnrollmentPurchase Blast$599
Posted in: Insulin Delivery, Other Jan 11 | 2023JPM 2023 Day 3: ESPR, IONS, EMBC, AMRN, and VTRSPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 10 | 2023JPM 2023 Day 2: LLY, ABT, PODD, SNY, AZN, MRK, and GSK; Sernova Advances T1DM Cell Pouch Technology; Pfizer Initiates New Ph1 Oral GLP-1RA TrialPurchase Blast$599
Posted in: Glucose Monitoring, Other Jan 09 | 2023JPM 2023 Day 1: DXCM, MDT, PFE, AMGN, VRTX, NVS, CYTK, TDOC, ARWR, and AMGN; AZ Acquires CinCor; Viking Completes Ph2b NASH Enrollment; Ionis Sells Pelacarsen RoyaltiesPurchase Blast
$599
Posted in: Other Jan 06 | 2023Madrigal Announces Additional Positive MAESTRO-NASH Data; Bluebird Sells Second PRV to BMS for $95MPurchase Blast
$599
Posted in: Other Jan 05 | 2023Inventiva Updates Lanifibranor NASH Development Program; Galectin Completes Ph2b/3 NAVIGATE Study Enrollment; Novo Signs Stemcell Deal with FujifilmPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Jan 04 | 2023Holiday Hangover: Novo's Wegovy/Ozempic Featured on 60 Minutes; Intercept OCA NASH NDA Refiled; Amgen Initiates Ph2 AMG 133 Obesity Trial; Steven Russell Joins Beta Bionics; Novo’s Third Cagrisema Ph3 Trial Initiated; Wegovy Pediatric Indication; Lannett Bs-Insulin Updates; Equillium and Metacrine Terminate Merger; and MorePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA + Basal, Other Dec 22 | 2022Lilly Initiates Final Ph3 QWINT Trial; Madrigal Announces $300M+ in Financing Events to Advance Resmetirom; Akebia Receives Interim Response to Appeal for Vadadustat CRLPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 21 | 2022Medtronic InPen App Recall; Libre 3 + Ypsomed AID Available in Germany; Altimmune Positive Pemvidutide NAFLD Data; Embecta CY Q3 ’22 Earnings Update; Alnylam Submits ALN-KHK CTA for T2DM; Biocorp Receives EU Medical Device CertificationPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Dec 19 | 2022Madrigal Wins Big with Ph3 NASH Data; Novo Expands Partnership for Dose Check; AZ Announces DELIVER Positive CHMP OpinionPurchase Blast
$599
Posted in: Other, SGLT2i Dec 16 | 2022Lilly Partners with Sosei Heptares for Metabolic Drug Discovery; FIGARO-DKD and DELIVER Positive CHMP OpinionsPurchase Blast
$599
Posted in: Other Dec 15 | 2022Alnylam Hosts 2022 R&D Day; Movano Health Initiates First Beta Program for Smart RingPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Dec 14 | 2022Tandem Acquires Sigi Patch Pump; Novo Reports Ozempic Supply Shortages; Novo Initiates Second 7.2mg Sema Ph3 Trial in T2DM; Cytokinetics Host Post-adcom Investor CallPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other Dec 13 | 2022Lilly Green Lights Two Next-Gen Incretin Ph3 Programs; Lilly 2023 Guidance CallPurchase Blast
$599
Posted in: GLP-1RA, Other Dec 12 | 2022Pfizer Hosts 2022 R&D Day; Novo Initiates 7.2mg Sema Ph3 Obesity Trial; ADA 2023 Diabetes SoC Guidelines; December CHMP AgendaPurchase Blast
$599
Posted in: Insulin Delivery, Other Dec 09 | 2022Lilly Ends Ypsomed Partnership; Cytokinetics Adcom Documents AvailablePurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery Dec 07 | 2022Esperion’s CLEAR Outcomes CVOT Meets Primary Endpoint; Biocorp’s Mallya Receives FDA 510(k) Clearance; Jardiance Meets Primary Endpoint in Pediatric Trial; MediciNova MN-001 (tipelukast) T2DM and NAFLD Ph2 Data; Daewoong Looks to Commercialize Enavogliflozin GloballyPurchase Blast